Onco-Nephrology
Symposium

THURSDAY, SEPTEMBER 17, 2026

7:00-7:30 am

Registration / Breakfast

7:30-7:40 am

Welcome From Course Directors

Shruti Gupta; Raad Chowdhury

7:40-7:50 am

Welcome Message from a Pioneer

Joseph Bonventre

7:50-8:15 am

What Do BMT Docs Wish Nephrologists Knew about HSCT? (Includes Q&A)

Corey Cutler

8:15-8:40 am

Changing Diagnostic and Treatment Landscape of HSCT-TMA (Includes Q&A)

Sumithra Vasu

8:40-9:05 am

Cancer and Complementology (Includes Q&A)

Anuja Java

9:05-9:30 am

Murine Models and Immune Therapy: What Can Mice Teach us About AIN? (Includes Q&A)

Sandra Herrmann

9:30-9:40 am

Break

9:40-10:05 am

Beyond Biopsy: Biomarkers and Treatments for ICI-AKI (Includes Q&A)

Meghan Sise

10:05-10:30 am

Lessons from Non-Renal Immune Related Adverse Events (Includes Q&A)

Elad Sharon

10:30-11:10 am

ICI-GN: A Conundrum (Includes Q&A)

Meghan Sise; Shruti Gupta; Abdullah Jalal; Ala Abudayyeh

11:10 am-12:10 pm

Lunch Break / Poster Review

12:10-12:30 pm

Toxicities of CAR-T and CAR-Treg

Sarah Nikiforow

12:30-12:50 pm

How Tumor Infiltrating Lymphocytes are Transforming Cancer Treatment

Allison Betof

12:50-1:00 pm

Q&A

Sarah Nikiforow; Allison Betof

1:00-1:25 pm

MAGnificent properties of Cisplatin: mitigating risk and managing AKI (Includes Q&A)

Edgar Jaimes

1:25-1:50 pm

Target Trial Emulation in Onconephrology (Includes Q&A)

David Leaf

1:50-2:15 pm

What's the GFR!? Current Challenges in Cancer and Future Opportunities (Includes Q&A)

Aisha Shaikh

2:15-2:40 pm

How Would I Dose Chemotherapy? A Case Review (Includes Q&A)

Abhijat Kitchlu

2:40-2:50 pm

Break

2:50-3:15 pm

Podocytes: An Innocent Bystander in Cancer (Includes Q&A)

Astrid Weins

3:15-3:40 pm

Novel Treatments for Proteinuria and Hypertension: Is there a Role for Endothelin Inhibitors? (Includes Q&A)

Api Chewcharat

3:40-4:05 pm

SGLT2is: Are they a Miracle For Cancer- Associated Nephrotoxicity Too? (Includes Q&A)

María José Soler

4:05-4:30 pm

Immune Complex Disease in Cancer: Future of Antigens (Includes Q&A)

Sujal Shah

4:30-5:10 pm

Nephrocentric vs Nephrotolerant: When is it Safe to Rechallenge? (Includes Q&A)

Biruh Workeneh; Astrid Weins; Harish Seethapathy; Aisha Shaikh

5:10-5:35 pm

Palliative Care in Onconephrology: Symptom Management and Decision Support (Includes Q&A)

Samantha Gelfand

5:35-5:45 pm

Adjourn

FRIDAY, SEPTEMBER 18, 2026

7:00-7:30 am

Registration / Breakfast

7:30-7:55 am

The Other Renal Amyloids: It's not ALL about AL Amyloid (Includes Q&A)

Vaishali Sanchorawala

7:55-8:20 am

Pathophysiology of Cancer Therapy and Cardiotoxicity (Includes Q&A)

Anju Nohria

8:20-8:45 am

MGUS to Myeloma: Bench to the Bedside (Includes Q&A)

Nikhil Munshi

8:45-9:05 am

IKMG Update on MGRS: Future Associations and Mechanisms (Includes Q&A)

Samih H. Nasr

9:05-9:25 am

How do Immunoglobulins Cause Kidney Damage?

Christophe Sirac

9:25-9:35 am

Q&A

Samih H. Nasr; Christophe Sirac

9:35-9:45 am

Break

9:45-10:10 am

The Onconephrology Jeopardy Challenge (Includes Q&A)

Shruti Gupta; Kenar Jhaveri

10:10-10:35 am

How I Manage IgM Disease and Systemic Impact (Includes Q&A)

Jorge J. Castillo

10:35-11:00 am

Light Chain Cast Nephropathy: Beyond Plex (CAR-T, Bispecific) (Includes Q&A)

Nelson Leung

11:00-11:25 am

The Clone That Stole the Gift: Transplant MGRS Case Review (Includes Q&A)

Christopher Blosser; Raad Chowdhury

11:25-11:50 am

Post Kidney Transplant Lymphoproliferative Disorders: Perspectives from a Transplant Nephrologist (Includes Q&A)

Christopher Blosser

11:50 am-12:30 pm

The War Against Light Chains: A Case Debate (Includes Q&A)

Raad Chowdhury; Sujal Shah; Nelson Leung; Kenar Jhaveri

12:30-12:40 pm

Final Reflections / Poster Winners

12:40-1:00 pm

Break

1:00-1:30 pm

Non CME Event: Tour of Dana-Farber, Brigham, Harvard Medical School (Group Photo at HMS Quad)

ABSTRACTS

1 Endothelin Receptor Antagonist for Anti Vascular Endothelial Growth Factor signaling pathway inhibitor Induced hypertension and or proteinuria.pdf

2 Unmasking the Brush Border_ AntiLRP2 (Megalin) Nephropathy in the Setting of Immune Checkpoint Inhibitor Therapy.pdf

3 Severe Acute Kidney Injury Following Liver Ablation_A Case Series.pdf

4 AKI Following Bispecific T-Cell Engager Therapy in Hematologic Malignancies_ A Multicenter Cohort Study.pdf

5 Prevalence of Malignancies Among Adult Kidney Transplant Recipients in Colombia_ Analysis of the National Health Registry 2019_2023.pdf

6 Overall survival with sequential systemic anticancer therapy and first-line response in metastatic renal cell carcinoma with ESKD_ a real world analysis.pdf

7 Safety of kidney biopsy in the oncologic populations_ a single center experience.pdf

8 Subclinical Glomerular Pathology in Patients with Solid Tumors_ An Ongoing Multicenter Histopathological, Immunofluorescence and Electron Microscopy Study.pdf

9 Biomarkers of Kidney Injury and Recovery in Patients with Multiple Myeloma Receiving Daratumumab.pdf

10 Cancer Associated Kidney Alterations_ Assessing Current and Identifying Novel Biomarkers.pdf

11 IgA Nephropathy in cancer patients_ either tumor-related or immunotherapy induced immune dysregulation.pdf

12 Bladder Cancer Mortality in Alabama (1999–2020)_ A County_Level Analysis of Racial and Sex_Based Disparities.pdf

13 Resolution of Bevacizumab_Associated Hypertension and Proteinuria After Drug Cessation In Patients with OBGYN Cancers_ A Real-World Cohort Study.pdf

14 IgG1 Heavy Chain Deposition Disease with Fibrillary Glomerulonephritis as a Manifestation of MGRS.pdf

15 Mortality from Multiple Myeloma and Plasma Cell Neoplasms in Alabama_ A 22-Year County-Level Disparity Analysis.pdf

16 Effects of Myeloid-Cell-Specific ZEB1 Deletion in a Repeated Low-Dose Cisplatin Remote Tumor Model.pdf

17 Impact of difference in estimated glomerular filtration rate based on creatinine and cystatin on the overall survival of patients with cancer.pdf

18 Post-Haematopoietic Stem Cell Transplant Nephrotic Syndrome_ A Single-centre experience of histological patterns, management and outcomes.pdf

19 Practice Patterns and Perspectives of Indian Oncologists in the Management of Immune Checkpoint Inhibitor–Associated Acute Kidney Injury_ A National Case - vignette-Based Survey.pdf

20 Complement-Dependent Killing Activity in Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy.pdf

21 Building a Transplant Onconephrology Program_ A Quality Improvement Initiative at a Tertiary Referral Center.pdf

22 The Paradox and the Price_ Renal Fallout of Immune Triumph in Cancer Care.pdf

23 Creatinine-Cystatin C Discordance in Hematopoietic Stem Cell Transplant Recipients with Neurotoxicity_ A Case Series.docx.pdf

24 Patient characteristics and clinical trajectories in an onconephrology clinic_ data from a single-center prospective clinic registry.pdf

25 The Curious Case of Hyponatremia.pdf

26 Tubulointerstitial nephritis associated with IgG4-Related Disease.pdf

27 Balancing Oncologic Benefit and Allograft Survival_ Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma in a Kidney Transplant Recipient.pdf

28 Monoclonal Gammopathy of Renal Significance Presenting as Nephrotic Syndrome Secondary to AL Amyloid Nephropathy.pdf

29 A descriptive retrospective study of the management of patients with acute kidney injury during treatment with immune checkpoint inhibitors in a tertiary university hospital.pdf

30 A successful reintroduction of immune checkpoint inhibitor treatment after a biopsy proven Minimal Change Disease and Acute Interstitial Nephritis.pdf